Related references
Note: Only part of the references are listed.Hematopoietic stem cell transplantation for patients with AML in first complete remission
Jan J. Cornelissen et al.
BLOOD (2016)
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
Charles Craddock et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Daisuke Araki et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study
Nelli Bejanyan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Iskra Pusic et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
Stefan O. Ciurea et al.
BLOOD (2015)
Getting a handle on hereditary CEBPA mutations
Courtney D. DiNardo
BLOOD (2015)
Current challenges in clinical development of targeted therapies: the case of acute myeloid leukemia
Elihu Estey et al.
BLOOD (2015)
Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation
Christoph Schmid et al.
BLOOD (2015)
Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
Ahmad Antar et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Sorafenib Treatment Following Hematopoietic Stem Cell Transplant in Pediatric FLT3/ITD Acute Myeloid Leukemia
Katherine Tarlock et al.
PEDIATRIC BLOOD & CANCER (2015)
Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies
Antonio Di Stasi et al.
FRONTIERS IN IMMUNOLOGY (2015)
Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia
Gaku Oshikawa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia
Eolia Brissot et al.
HAEMATOLOGICA (2015)
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant
Sarah L. Sammons et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA
Nicolas Duployez et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia
Michael R. Grunwald et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
Yi-Bin Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation
Melissa Alsina et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for prime time?
David Grimwade et al.
BLOOD (2014)
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation
Philippe Armand et al.
BLOOD (2014)
In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification
Yu Wang et al.
BLOOD (2014)
Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML
C. Anthias et al.
BONE MARROW TRANSPLANTATION (2014)
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the US Registry
Loren Gragert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Seth A. Wander et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
Roland B. Walter et al.
BLOOD (2013)
Acute Myeloid Leukemia in First Remission: To Choose Transplantation or Not?
Richard M. Stone
JOURNAL OF CLINICAL ONCOLOGY (2013)
Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Maintenance Therapy With Tyrosine Kinase Inhibitors After Transplant in Patients With Chronic Myeloid Leukemia
Merav Bar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
T. Schroeder et al.
LEUKEMIA (2013)
Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
Aude G. Chapuis et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine
T. Maeda et al.
BLOOD CANCER JOURNAL (2013)
Prophylactic and Preemptive Therapy with Dasatinib after Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Giovanni Caocci et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2012)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Oliver C. Goodyear et al.
BLOOD (2012)
A disease risk index for patients undergoing allogeneic stem cell transplantation
Philippe Armand et al.
BLOOD (2012)
Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study
Yu Wang et al.
CLINICAL TRANSPLANTATION (2012)
Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial
Katja Sockel et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease
A. Tsuboi et al.
LEUKEMIA (2012)
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U. Platzbecker et al.
LEUKEMIA (2012)
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
Evelien Kneppers et al.
BLOOD (2011)
Pitfalls of vaccinations with WT1-, Proteinase3-and MUC1-derived peptides in combination with MontanideISA51 and CpG7909
Juergen Kuball et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies
Katayoun Rezvani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
Mohamed L. Sorror et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Jan Kroenke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Roland B. Walter et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation
John R. Wingard et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Maintenance Therapy With Low-Dose Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Marcos de Lima et al.
CANCER (2010)
Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias
William Blum et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Impact of Minimal Residual Disease in CBFB-MYH11-Positive Acute Myeloid Leukemia
Andrea Corbacioglu et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Relapse after allogeneic stem cell transplantation
A. John Barrett et al.
EXPERT REVIEW OF HEMATOLOGY (2010)
Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome
Masaki Yasukawa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
Susanne Schnittger et al.
BLOOD (2009)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Ulrich Keilholz et al.
BLOOD (2009)
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials
John Koreth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
David Grimwade et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Donor lymphocyte infusions for acute myeloid leukaemia
Robert J. Soiffer
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2008)
Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia - Feasibility and safety study
Xiao-Jun Huang et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2008)
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
Katayoun Rezvani et al.
BLOOD (2008)
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia
Eduardo Olavarria et al.
BLOOD (2007)
NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia
Michela Palmisano et al.
HAEMATOLOGICA (2007)
Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity
K. Rezvani et al.
CYTOTHERAPY (2007)
Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples
J. Cloos et al.
LEUKEMIA (2006)
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]
G Perea et al.
LEUKEMIA (2006)
Transplantation of allogeneic CD34+selected cells followed by early T-cell add-backs:: favorable results in acute and chronic myeloid leukemia
G Kobbe et al.
CYTOTHERAPY (2004)
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia
W Kern et al.
BLOOD (2004)
Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation
BR Dey et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2003)
Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk, acute leukaemias if complete donor chimerism can be achieved
G Massenkeil et al.
BONE MARROW TRANSPLANTATION (2003)
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia:: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors
PD Kottaridis et al.
BLOOD (2002)
Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease
M de Lima et al.
BONE MARROW TRANSPLANTATION (2001)
Share Paper
